Mirum Pharmaceuticals Price Target Maintained With a $66.00/Share by HC Wainwright & Co.
Mirum Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Buy Rating Affirmed for Mirum Pharmaceuticals Amidst Label Expansion and Positive EU Authorization
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $69
Mirum Pharmaceuticals (MIRM) Gets a Buy From JMP Securities
Buy Rating Justified: Mirum Pharmaceuticals' Growth Prospects and Market Expansion Post-Livmarli Approval
HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $66 Price Target
Mirum Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Mirum Pharmaceuticals on LIVMARLI's EU Approval and Positive Revenue Projections
Mirum Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $66 Price Target
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $57
JMP Securities Adjusts Price Target on Mirum Pharmaceuticals to $68 From $66, Maintains Market Outperform Rating
Stifel Reiterates Buy on Mirum Pharmaceuticals, Maintains $48 Price Target
Mirum Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $50 From $45, Maintains Overweight Rating
Mirum Pharmaceuticals Analyst Ratings
Mirum Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $58 Price Target